MEHA Functional Brands Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1837254 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-2,452.2%
TTM EPS YoY-340.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin55.8%
Operating margin-51.8%
Net margin-142.5%
FCF margin—
EBITDA margin-51.6%
Returns
ROE—
ROA-132.2%
ROIC (approx.)—
Asset turnover0.93x
Leverage & solvency
Liabilities / assets160.0%
Debt / equity—
Current ratio0.30x
Interest coverage-7.66x
Cash quality & payout
Operating cash flow / net income0.40x
Accruals ratio-79.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.61M | $6.57M |
| Cost of revenue | $3.13M | $2.96M |
| Gross profit | $3.48M | $3.61M |
| SG&A expense | $4.25M | $3.26M |
| Operating income | -$1.40M | -$229,092 |
| Interest expense | $402,398 | $331,836 |
| Net income | $758,478 | -$559,356 |
| EBITDA | -$1.38M | -$180,721 |
| EPS (basic) | 0.08 | -0.08 |
| EPS (diluted) | 0.01 | -0.08 |
| Weighted avg. shares (diluted) | 85.12M | 6.69M |
| Balance sheet | ||
| Cash & equivalents | $2.73M | $211,642 |
| Receivables | $518,474 | $303,471 |
| Inventory | $1.55M | $1.71M |
| Current assets | $5.19M | $2.86M |
| PP&E, net | $37,379 | $49,564 |
| Goodwill | $818,139 | $818,139 |
| Intangibles | $1.40M | $1.44M |
| Total assets | $9.11M | $7.17M |
| Current liabilities | $5.75M | $5.20M |
| Short-term debt | $154,957 | — |
| Long-term debt | $140,468 | — |
| Total debt | $295,425 | — |
| Total liabilities | $7.57M | $7.29M |
| Shareholders' equity | $1.54M | -$118,577 |
| Net debt | -$2.43M | — |
| Shares outstanding | 18.70M | 6.69M |
| Cash flow statement | ||
| Operating cash flow | -$1.27M | $1,990 |
| Capital expenditure | $8,513 | $1,881 |
| Free cash flow | -$1.28M | $109 |
| Investing cash flow | -$8,513 | -$1,881 |
| Financing cash flow | $3.80M | -$162,902 |
| Depreciation & amortization | $20,698 | $48,371 |
| Stock-based compensation | $543,068 | $414,900 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.